• Bibliometric analysis
• CiteSpace
• Gastric cancer
• Signet ring cell carcinoma
• VOSviewer

• Colorectal cancer
• Gastric cancer
• Metastasis
• Predictive model
• SEER
• Signet ring cell carcinoma

• Humans
• Carcinoma, Signet Ring Cell/pathology
• Carcinoma, Signet Ring Cell/mortality
• Male
• Female
• Middle Aged
• Prognosis
• Nomograms
• Aged
• Stomach Neoplasms/pathology
• Stomach Neoplasms/mortality
• SEER Program
• Risk Factors
• Neoplasm Metastasis
• Gastrointestinal Neoplasms/pathology
• Gastrointestinal Neoplasms/mortality
• Adult
• Colorectal Neoplasms/pathology
• Colorectal Neoplasms/mortality

• ZR2020QH033 Natural Science Foundation of Shandong Province

• Diffuse gastric cancer
• Gastric cancer
• Oesophageal cancer
• Poorly cohesive gastric cancer
• Signet ring cell carcinoma

• Alcian blue
• Gastric
• Periodic acid-Schiff
• Prognosis
• Signet ring cell carcinoma

• Clinical characteristic
• Gastrointestinal
• Molecular characteristic
• Signet ring cell carcinoma
• Treatment

• Humans
• Gastrointestinal Neoplasms/therapy
• Adenocarcinoma
• Carcinoma, Signet Ring Cell/diagnosis
• Carcinoma, Signet Ring Cell/pathology
• Biomarkers

• Gastric cancer
• Nomogram
• Overall survival
• Prognosis
• Signet-ring cell carcinoma (SRCC)

• Humans
• Stomach Neoplasms/surgery
• Retrospective Studies
• Gastrectomy
• Prognosis
• Carcinoma, Signet Ring Cell/surgery

• gastric cancer
• poorly cohesive carcinoma
• signet ring cell

• ZR2021MH108 Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation)

• PD-1 inhibitor
• efficacy
• gastric cancer
• gastric signet-ring cell carcinoma
• predictive factors

While the incidence of gastric cancer (GC) in general has decreased worldwide in recent decades, the incidence of diffuse cancer historically comprising poorly cohesive cells-GC (PCC-GC) and including signet ring cell cancer is rising. Literature concerning PCC-GC is scarce and unclear, mostly due to a large variety of historically used definitions and classifications. Compared to other histological subtypes of GC, PCC-GC is nevertheless characterized by a distinct set of epidemiological, histological and clinical features which require a specific diagnostic and therapeutic approach. The aim of this review was to provide an update on the definition, classification and therapeutic strategies of PCC-GC. We focus on the updated histological definition of PCC-GC, along with its implications on future treatment strategies and study design. Also, specific considerations in the diagnostic management are discussed. Finally, the impact of some recent developments in the therapeutic management of GC in general such as the recently validated taxane-based regimens (5-Fluorouracil, leucovorin, oxaliplatin and docetaxel), the use of hyperthermic intraperitoneal chemotherapy as well as pressurized intraperitoneal aerosol chemotherapy and targeted therapy have been reviewed in depth for their relative importance for PCC-GC in particular.

• Poorly cohesive cells gastric carcinoma
• Review
• Definition
• Classification
• Therapeutic management

• Carcinoma, Signet Ring Cell
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Prognosis
• Retrospective Studies
• Risk Factors
• Stomach Neoplasms

• HIPEC
• PIPAC
• cytoreductive surgery
• gastric cancer
• intraperitoneal chemotherapy
• peritoneal metastases

• Drug resistance
• Intracellular mucin 20
• Mitochondrial calcium homeostasis
• Mitochondrial membrane potential
• Signet ring cell carcinoma

• Animals
• Calcium/therapeutic use
• Carcinoma, Signet Ring Cell/pathology
• Cisplatin
• Drug Resistance
• Heterografts
• Homeostasis
• Humans
• Mice
• Mucins
• Stomach Neoplasms/drug therapy
• Stomach Neoplasms/genetics
• Stomach Neoplasms/metabolism

• gastric carcinoma
• immunohistochemical staining
• peroxisome proliferator-activated receptor-α

Signet ring cell carcinoma (SRCC) is a poorly cohesive subtype of gastric cancer. It is more aggressive than other types of gastric cancer. There is no special method for its treatment, but gastrectomy and lymphadenectomy is the standard approach. The aim of this study is to investigate postoperative outcomes of D1 lymphadenectomy and D1(+)lymphadenectomy in gastric SRCC.

A total of 358 cases whohad a gastrectomy performed forthe diagnosis of gastric cancer between 2013 and 2019 in Ankara University Medical Faculty, Surgical Oncology Department were retrospectively investigated. In all, 128 of the cases had SRCC in the final pathology. We separated the cases into two types,D1 lymphadenectomy and D1(+) lymphadenectomy. The 5-year survival, early mortality, hospital mortality and postoperative complication rates were evaluated.

There were 59 patients in the D1 group and 64 patients in the D1(+) group.Metastatic lymph node amount and therefore N stage was found to be significantly higher in the D1(+) group (p=0.00 and p=0.03, respectively). Postoperative chyle fistula was found to be significantly higher in the D1(+) group (p=0.003). There was no statistically significant difference between the groups with regard tomean survival (p=0.065);the 5-year mean survival was 21% in the D1 group and 7% in the D1(+) group. Present findings suggest that extended lymphadenectomy does not provide a benefit in cases of SRCC.

• D1(+) lymphadenectomy
• Signet ring cell
• hospital mortality
• long-term survival
• peritoneal seeding

• adenocarcinoma
• gastric cancer
• histopathology
• signet ring cell carcinoma

Signet ring cell carcinoma (SRCC) of the stomach is a rare type of cancer with a slowly rising incidence. It tends to be more difficult to detect by pathologists, mainly due to its cellular morphology and diffuse invasion manner, and it has poor prognosis when detected at an advanced stage. Computational pathology tools that can assist pathologists in detecting SRCC would be of a massive benefit. In this paper, we trained deep learning models using transfer learning, fully-supervised learning, and weakly-supervised learning to predict SRCC in Whole Slide Images (WSIs) using a training set of 1,765 WSIs. We evaluated the models on two different test sets (n = 999, n = 455). The best model achieved a ROC-AUC of at least 0.99 on all two test sets, setting a top baseline performance for SRCC WSI classification.

• deep learning
• gastric cancer
• multiple-instance learning
• signet ring cell carcinoma
• transfer learning
• weakly-supervised learning

• Area Under Curve
• Carcinoma, Signet Ring Cell/classification
• Carcinoma, Signet Ring Cell/diagnosis
• Carcinoma, Signet Ring Cell/pathology
• Computational Biology
• Deep Learning
• False Negative Reactions
• False Positive Reactions
• Humans
• ROC Curve
• Stomach Neoplasms/classification
• Stomach Neoplasms/diagnosis
• Stomach Neoplasms/pathology
• Supervised Machine Learning

The aim of our study was to develop a nomogram model to predict overall survival (OS) and cancer-specific survival (CSS) in patients with gastric signet ring cell carcinoma (GSRC).

GSRC patients from 2004 to 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) database and randomly assigned to the training and validation sets. Multivariate Cox regression analyses screened for OS and CSS independent risk factors and nomograms were constructed.

A total of 7,149 eligible GSRC patients were identified, including 4,766 in the training set and 2,383 in the validation set. Multivariate Cox regression analysis showed that gender, marital status, race, AJCC stage, TNM stage, surgery and chemotherapy were independent risk factors for both OS and CSS. Based on the results of the multivariate Cox regression analysis, prognostic nomograms were constructed for OS and CSS. In the training set, the C-index was 0.754 (95% CI = 0.746-0.762) for the OS nomogram and 0.762 (95% CI: 0.753-0.771) for the CSS nomogram. In the internal validation, the C-index for the OS nomogram was 0.758 (95% CI: 0.746-0.770), while the C-index for the CSS nomogram was 0.762 (95% CI: 0.749-0.775). Compared with TNM stage and SEER stage, the nomogram had better predictive ability. In addition, the calibration curves also showed good consistency between the predicted and actual 3-year and 5-year OS and CSS.

The nomogram can effectively predict OS and CSS in patients with GSRC, which may help clinicians to personalize prognostic assessments and clinical decisions.

• SEER
• cancer-specific survival
• gastric signet ring cell carcinoma
• nomogram
• overall survival

• biological behavior
• gastric neoplasm
• meta-analysis
• prognosis
• signet-ring cell carcinoma

Signet ring cell carcinoma (SRC) is a rare histological subtype of gallbladder adenocarcinoma. The current study evaluates the clinicopathologic features and prognosis of SRC.

Patients with adenocarcinoma of the gallbladder were identified in the Surveillance, Epidemiology, and End Results database from 1973 to 2016. Overall survival (OS) and cancer-specific survival (CSS) of patients who had SRC were compared with those of patients who had non-SRC using Cox regression and propensity score methods.

Of 22,781 gallbladder adenocarcinomas retrieved, 377 (1.7%) were SRC and the other 22,404 were non-SRC. SRC was more significantly associated with older age, female gender, poor differentiation, advanced tumor stage, lymph node metastasis, distant metastasis, and advanced AJCC stage. The 5-year OS and CSS in the SRC group were 7.2 and 6.5%, respectively, both of which were significantly worse than the 13.2 and 13.3% seen in the SRC group (P = 0.002 and P = 0.012, respectively). This survival disadvantage persisted in multivariable analyses [hazard ratio (HR) = 1.256, P = 0.021 and HR = 1.211, P = 0.036] and after propensity score matching (OS: HR = 1.341, P = 0.012 and CSS: HR = 1.625, P = 0.005). Surgery in combination with chemotherapy improved OS of gallbladder SRC patients compared with surgery alone (HR = 0.726, P = 0.036) or chemotherapy alone (HR = 0.433, P < 0.001).

Patients with SRC of the gallbladder have distinct clinicopathological features with poor prognosis. Surgery in combination with chemotherapy can improve survival.

• Gallbladder
• Prognosis
• Signet ring cell carcinoma
• Surgery

• KRAS
• amplification
• gastric signet-ring cell carcinoma (SRCC)
• point mutation

Background: There is controversy about the characteristics and prognostic implications of signet ring cell gastric cancers and non-signet ring cell gastric cancers.

Objective: This study aims to evaluate clinicopathological characteristics and prognoses of signet ring cell carcinoma (SRCC) and non-signet ring cell carcinoma (NSRCC) of stomach.

Methods: Studies compared between SRCC and NSRCC of the stomach after gastrectomy and published before September 1st, 2020, in the PubMed, Cochrane, and Embase databases, were identified systematically.

Results: A total of 2,865 studies were screened, and 36 studies were included, with 19,174 patients in the SRCC group and 55,942 patients in the NSRCC group. SRCC patients were younger in age (P < 0.001), less likely to be male patients (P < 0.001), more afflicted with upper third lesions (P < 0.001), and presenting with more Borrmann type IV tumors (P = 0.005) than NSRCC patients. Lymph nodes metastasis was similar between SRCC and NSRCC patients with advanced tumor stage (OR: 0.86, 95% CI: 0.671.10, P = 0.23), but lower in the SRCC than NSRCC patients with early tumor stage (OR: 0.73; 95% CI: 0.560.98, P = 0.02). SRCC patients had comparable survival outcomes with NSRCC patients for early gastric cancers (HR: 1.05, 95% CI: 0.651.68, P < 0.001) but had significantly poor prognosis for patients with advanced tumor stage (HR: 1.50, 95% CI: 1.281.76, P < 0.001).

Conclusions: Signet ring cell carcinomas of the stomach are an increasingly common histopathological subtype of gastric cancers. These kinds of patients tend to be younger in age and more often female. Although, signet ring cell gastric cancer is a negative prognostic factor for patients with advanced stage. The difference is that for early stage of signet ring cell gastric cancers, it has low lymph nodes metastasis rate and comparable prognosis with non-signet ring cell cancers.

• gastric cancer
• prognosis
• sex
• signet ring cell
• stage

• S-1
• adjuvant
• gastrectomy
• gastric cancer (GC)

Gastric cancer is the fifth most common cancer and the third most common cause of cancer-related deaths in the world. In this study, we aimed to evaluate the impact of clinicopathological factors on overall survival in the patients who underwent curative-intent gastrectomy due to gastric adenocarcinoma.

The medical records of 644 patients who underwent gastrectomy between January 2007 and January 2017 in our clinic were retrospectively reviewed. Among these patients, 359 patients were included in this study. The impact of several prognostic factors on survival was investigated.

The mean age was 59.2±11.6 (29-83). Male/female ratio was 2.12. The median follow-up time was 19 months (CI=10.1-31.1). Median overall survival was 23±2.3 months (CI=18.3-27.6). Splenectomy, R1 (microscopically incomplete) resection, and advanced stage were independent risk factors for poor prognosis.

R1 resection, splenectomy, and advanced TNM stage were associated with poor prognosis in gastric cancer. Splenectomy should be avoided in the absence of direct invasion of the tumour or metastasis of lymph nodes on splenic hilum to prevent postoperative infectious complication-related mortality.

• Curative-intent gastrectomy
• gastric adenocarcinoma
• overall survival
• prognostic factor
• splenectomy

The p53 family is a complex family of transcription factors with different cellular functions that are involved in several physiological processes. A massive amount of data has been accumulated on their critical role in the tumorigenesis and the aggressiveness of cancers of different origins. If common features are observed, there are numerous specificities that may reflect particularities of the tissues from which the cancers originated. In this regard, gastric cancer tumorigenesis is rather remarkable, as it is induced by bacterial and viral infections, various chemical carcinogens, and familial genetic alterations, which provide an example of the variety of molecular mechanisms responsible for cell transformation and how they impact the p53 family. This review summarizes the knowledge gathered from over 40 years of research on the role of the p53 family in gastric cancer, which still displays one of the most elevated mortality rates amongst all types of cancers.

Gastric cancer is one of the most aggressive cancers, with a median survival of 12 months. This illustrates its complexity and the lack of therapeutic options, such as personalized therapy, because predictive markers do not exist. Thus, gastric cancer remains mostly treated with cytotoxic chemotherapies. In addition, less than 20% of patients respond to immunotherapy. TP53 mutations are particularly frequent in gastric cancer (±50% and up to 70% in metastatic) and are considered an early event in the tumorigenic process. Alterations in the expression of other members of the p53 family, i.e., p63 and p73, have also been described. In this context, the role of the members of the p53 family and their isoforms have been investigated over the years, resulting in conflicting data. For instance, whether mutations of TP53 or the dysregulation of its homologs may represent biomarkers for aggressivity or response to therapy still remains a matter of debate. This uncertainty illustrates the lack of information on the molecular pathways involving the p53 family in gastric cancer. In this review, we summarize and discuss the most relevant molecular and clinical data on the role of the p53 family in gastric cancer and enumerate potential therapeutic innovative strategies.

• biomarker
• cell death
• chemotherapy
• gastric cancer
• immunotherapy
• isoforms
• metastasis
• p53 family
• personalized therapy
• tumor ecosystem

• Gastric cancer
• Histology type
• Prognostic factor
• Signet ring cell carcinoma
• Survival

• Linitis plastica (LP)
• case-control study
• digestive cancer
• endoscopic ultrasound (EUS)
• gastric cancer (GC)

• Gastric adenocarcinoma
• nomogram
• signet ring cell carcinoma
• survival

• CLDN18.2
• Gastric signet-ring cell carcinoma (gastric SRCC)
• next-generation sequencing (NGS)

Signet ring cell containing gastric cancer (SRCGC) is a rare subtype of gastric cancer, and its adjuvant therapy is based on general gastric cancer. However, the effectiveness of radiotherapy for those SRCGC patients remains unknown.

The purpose of the study was to analyze whether the addition of radiotherapy to adjuvant chemotherapy (CT) can benefit survival in resected SRCGC patients.

Patients with SRCGC, who underwent D2 gastrectomy followed by adjuvant chemotherapy or chemoradiotherapy (CRT), were retrospectively collected. According to the proportion of signet ring cells, patients were histologically classified as pure SRCGC (pSRCGC) containing 100% of signet ring cells, mixed SRCGC (mSRCGC) containing >50% of signet ring cells, and contaminated SRCGC (cSRCGC) containing <50% of signet ring cells. Among the 272 patients, 156 were treated by CT alone and 116 by CRT. The primary endpoint was 3-year overall survival rate (3-year OS rate).

With a median follow-up of 80.5 months, the 3-year OS rate was significantly higher in the CT group (70.5% vs. 58.6%, HR = 0.633, P = 0.017) compared with CRT group. Three independent characteristics were predictive of a poor overall survival: CRT treatment (P = 0.019), tumor size ≥5 cm (P < 0.001), and the presence of vessel invasion (P = 0.009). Subgroup analyses showed CRT significantly impaired prognosis in SRCGC patients in the cSRCGC subset, as well as lesions located in lower-middle sites, subtotal gastrectomy, male, <60 year, and no vessel invasion. Peritoneal was the most common recurrence site in SRCGC patients. The adverse events leukopenia and neutropenia were more common in the CRT group (P = 0.007).

Adjuvant chemoradiotherapy was associated with poor survival compared with adjuvant chemotherapy in SRCGC patients with D2 gastrectomy.

• adjuvant therapy
• chemoradiotherapy
• chemotherapy
• gastric cancer
• signet ring cell carcinoma

• cytoreductive surgery
• gastric cancer
• hyperthermic intraperitoneal chemotherapy
• intraperitoneal chemotherapy
• peritoneal surface malignancy
• signet-ring cell carcinoma

• Aged
• Antineoplastic Agents/administration & dosage
• Carcinoma, Signet Ring Cell/drug therapy
• Carcinoma, Signet Ring Cell/surgery
• Combined Modality Therapy
• Cytoreduction Surgical Procedures
• Humans
• Hyperthermia, Induced
• Male
• Stomach Neoplasms/drug therapy
• Stomach Neoplasms/surgery

• Gastric cancer
• histology type
• prognostic factor
• signet ring cell carcinoma
• survival

• Abdominal surgery
• Biological sciences
• Cancer surgery
• Gastric cancer
• Health sciences
• Pathology
• Poorly cohesive carcinoma
• Prognosis
• Survival

The aim of this study was to evaluate ¹⁸F-fluoro-2-deoxy-glucose (FDG) uptake patterns in primary tumors and metastatic lesions, and also to assess the diagnostic contribution of positron emission tomography/computed tomography (PET/CT) in the initial staging of gastric cancer (GC).

The total number of 341 patients with GC were included in this study. All ¹⁸F-FDG PET/CT imagings were performed for initial staging. The maximum standardized uptake value (SUV_max) of primary tumor, obtained from ¹⁸F-FDG PET/CT imaging was compared between subtypes of GC.

Mean SUV_max of 339 patients’ primary tumor was 12.9±8.6. The highest mean SUV_max was detected in patients with medullary subtype GC (17.8±9.9) while the lowest mean SUV_max (9.7±7.6) was seen in signet ring cell carcinoma (SRCC). The primary mean SUV_max was found statistically higher in tubular adenocarcinoma (TAC) group than SRCC group (p<0.001). Higher SUV_max values were found statistically significantly correlated with advanced age (aged ≥60) and increased tumor size (>3 cm) in patients with TAC (p=0.03). Primary tumor SUV_max was found statistically higher in regional lymph node (RLN) positive patients than in RLN negative patients in TAC and SRCC groups (p<0.001 and p=0.012, respectivelly). Also, in patients with SRCC, SUV_max was significantly higher in the distant metastatic group than in the group without metastasis (p=0.025).

Increased primary tumor SUV_max was associated with some of clinical parameters such as age and RLN metastasis in patients with TAC. However, there was no relationship between distant metastatic state and primary tumor ¹⁸F-FDG uptake in TAC. However, high SUV_max of primary tumor in SRCC was associated with regional and distant metastasis, and primary tumor ¹⁸F-FDG uptake may be a prognostic value for this subgroup.

• Gastric cancer
• 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)
• adenocarcinomas

• chemotherapy
• clinicopathological features
• gastric cancer
• prognostic factors
• signet ring cell carcinoma

• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Signet Ring Cell/mortality
• Carcinoma, Signet Ring Cell/pathology
• Female
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Neoplasm Grading
• Neoplasm Staging
• Prognosis
• Proportional Hazards Models
• Stomach Neoplasms/mortality
• Stomach Neoplasms/pathology
• Young Adult

• grants from Fujian Innovation project

• Gastric cancer
• Nomogram
• Propensity score
• Radiotherapy
• Signet ring cell carcinoma

• Shanghai Committee of Science and Technology

• appendiceal carcinoma
• colorectal carcinoma
• cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
• gastric carcinoma
• signet ring cell

Age is a prognostic factor for multiple malignancies. In this study, we aimed to assess the effect of age on the cancer-specific survival (CSS) of patients with gastric signet-ring cell carcinoma (SRC).

Information on patients with gastric SRC was extracted from the Surveillance, Epidemiology, and End Results database. Chi-squared tests were used to demonstrate distribution differences, and Kaplan-Meier analysis and Cox regression models were used to analyze the impact of age on CSS.

A total of 4596 patients were enrolled and divided into 3 subgroups according to age (<45, 45–74, and >74 years old). Higher percentages of T4, N2, and M1 disease were observed in the <45-year-old group (all P<0.001). Kaplan-Meier plots showed that the youngest group had the most favorable 5-year CSS rate (36.3%), which remained true after stratification according to tumor stage. Multivariate Cox regression models demonstrated a poorer survival outcome for >74-year-old than for <45-year-old patients (hazard ratio 1.841, 95% confidence interval 1.636–2.071; P<0.001).

Young age is associated with improved survival, even though younger patients generally present with a more advanced-stage disease.

Computed tomography (CT) scan is a key imaging technique in the staging of gastric adenocarcinoma and therapeutic management of patients. The aim of this study was to evaluate the performance of CT scan in the staging of parietal and metastatic invasion in gastric linitis plastica group.

A retrospective multicentric French study was conducted from January 2006 to December 2015 on patients with no metastatic gastric linitis plastica and operated by gastrec-tomy. A 2/1 matching based on pTNM stage and center was performed.

Fifty patients were included in the linitis plastica group and 100 in the control group. Patients from the linitis group were significantly different from those from the control group with a lower age at diagnosis, a more advanced histological lesion, a more frequent undiagnosed peritoneal carcinomatosis, and a higher risk of R1 resection. Sensitivity and specificity of CT scan for the diagnosis of lymph node involvement were 44% and 75%, respectively, in the linitis plastica group and 55% and 60%, respectively, in the control group. The sensitivity and specificity of CT scan for the T3–T4 parietal invasion were 26% and 100%, respectively, in the linitis group and 40% and 72%, respectively, in the control group.

CT scan has an equal sensitivity and specificity for the evaluation of lymph node and parietal involvement in gastric adenocarcinoma, including linitis plastica. CT scan remains the cornerstone of preoperative evaluation in gastric adenocarcinoma, including linitis plastica. However, CT presents a lack of sensitivity to diagnose low-volume peritoneal carcinomatosis.

• CT scan
• computed tomography
• gastric adenocarcinoma
• linitis

• Alaska Native
• Gastric cancer
• Gender
• Health disparities
• Helicobacter pylori

• Adult
• Aged
• Aged, 80 and over
• Alaska Natives/statistics & numerical data
• Carcinoma, Signet Ring Cell/diagnosis
• Carcinoma, Signet Ring Cell/epidemiology
• Carcinoma, Signet Ring Cell/pathology
• Carcinoma, Signet Ring Cell/therapy
• Early Detection of Cancer/statistics & numerical data
• Female
• Health Status Disparities
• Helicobacter pylori/isolation & purification
• Humans
• Incidence
• Lymph Nodes/pathology
• Male
• Middle Aged
• Retrospective Studies
• SEER Program/statistics & numerical data
• Sex Factors
• Stomach/microbiology
• Stomach/pathology
• Stomach/surgery
• Stomach Neoplasms/diagnosis
• Stomach Neoplasms/epidemiology
• Stomach Neoplasms/pathology
• Stomach Neoplasms/therapy
• Treatment Outcome
• United States/epidemiology
• White People/statistics & numerical data
• Young Adult

• P20 GM103395 NIGMS NIH HHS

• Antineoplastic Agents/therapeutic use
• Carcinoma, Signet Ring Cell/drug therapy
• Carcinoma, Signet Ring Cell/genetics
• Cell Line, Tumor
• Claudins/genetics
• Claudins/physiology
• Drug Resistance, Neoplasm/genetics
• Female
• GTPase-Activating Proteins/genetics
• GTPase-Activating Proteins/physiology
• Humans
• Male
• Mutant Chimeric Proteins
• Oxaliplatin/therapeutic use
• Retrospective Studies
• Stomach Neoplasms/drug therapy
• Stomach Neoplasms/genetics
• Treatment Outcome
• Whole Genome Sequencing

• 81522028 National Natural Science Foundation of China (National Science Foundation of China)